Veeva Systems (VEEV)
Connects life sciences development, quality, data, and commercial workflows in the cloud.
Something off on this page? Send us feedback.
Provides cloud software, data, and consulting for clinical development, regulatory, safety, quality, and commercial teams in life sciences. Revenue is predominantly subscription-based, and core applications connect regulated content and data on the proprietary Vault platform.
Organizes its life sciences portfolio into Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. The suites cover clinical trials, regulatory submissions, drug safety, manufacturing quality, CRM, commercial content, and healthcare-professional and de-identified patient data; implementation and business consulting supplement the software.
Builds core applications on the proprietary Vault platform, connecting content and data across regulated workflows. Customers range from global biopharma companies to emerging firms, while North America supplies most revenue and Europe is the next-largest region.
Earns most revenue from subscriptions. Life-sciences specialization supports validation and compliance requirements, while Vault CRM is replacing the Salesforce-based legacy CRM. Vault applications rely on Amazon Web Services, and some AI agents use third-party language models. Operates as a Delaware public benefit corporation.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | Wells Fargo | Reiterate | Rating: —Target: $320 | Target: $330 |
| Aug 27, 2026 | Truist Financial | Target | Target: $217 | Target: $305 |
| Aug 27, 2026 | Raymond James | Reiterate | Rating: —Target: $225 | Target: $330 |
| Aug 27, 2026 | RBC Capital | Reiterate | Rating: —Target: $250 | Target: $325 |
| Aug 27, 2026 | Evercore ISI | Target | Target: $185 | Target: $250 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $7.24B · Total debt $151.7M · Total assets $9.06B · Shareholders' equity $7.43B
- Revenue
- $928.0M
- Operating income
- $275.0M
- Net income
- $273.4M
No dividends on record.
| Institutions | 90.26% | 146.14M shares | |
|---|---|---|---|
| 1,108 holders · as of Jun 30, 2026 | |||
| Insiders | 23.48% | 38.02M shares | |
| 19 holders · as of Sep 21, 2026 | |||
| Strategic holders | 5.47% | 8.86M shares | |
| 1 holder · as of Feb 7, 2022 | |||
| Adds to | 119.21% | ||
161.91M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 119.21%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Peter P. Gassner1Insiderdirector, officer: Chief Executive Officer | 18.47% | 17.68M | filed Dec 13, 2023 |
BlackRock, Inc.Institution | 7.94% | 12.86M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 5.99% | 9.69M | as of Jun 30, 2026 |
BlackRock, Inc.Strategic | 5.47% | 8.86M | filed Feb 7, 2022 |
Vanguard Portfolio Management LLCInstitution | 4.58% | 7.41M | as of Jun 30, 2026 |
- Peter P. Gassner's transaction reports restate only vehicles that traded; the 2022 ownership statement (17.68M) plus the 12.23M net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −1,000 | $265.20 |
| Sep 9, 2026 | Priscilla Hung | director | −750 | $261.04 |
| Aug 27, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −10,000 | $281.33 |
| Aug 13, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −36,000 | $250.23 |
| Jul 16, 2026 | Thomas D. Schwenger | officer: Pres. & Chief Customer Officer | −5,000 | $200.00 |
- IQVIA
Pharma data incumbent competing in CRM, HCP data, and commercial analytics.
- Salesforce
Horizontal CRM giant turned direct pharma rival with Agentforce Life Sciences.
- Oracle
Enterprise tech giant competing in eClinical, pharmacovigilance, and R&D data.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Veeva Systems | $261.23 | −0.03% | $42.45B | 43.0 | 27.1 | 12.3 | +17.6% |
| IQVIA | $268.43 | −0.54% | $44.42B | 33.5 | 19.7 | 2.6 | +8.7% |
| Salesforce | $237.82 | +0.59% | $193.63B | 21.6 | 16.2 | 4.4 | +10.8% |
| Oracle | $153.36 | +3.23% | $427.95B | 23.3 | 18.0 | 6.0 | +29.6% |
| Median | 23.3 | 18.0 | 4.4 | +10.8% |